Theaprin Pharmaceuticals has developed a novel delivery form of aspirin to alleviate pain more safely and quickly. Patients suffering from heart attacks, strokes, arthritis, and dysphagia (difficulty swallowing) can all benefit from aspirin that is easily absorbed under the tongue, eliminating potential swallowing and gastrointestinal issues. Theaprin will also be a category leader as a medicine to ease animals’ suffering from pain and arthritis.

​Theaprin can be delivered intravenously and sublingually (dissolving under the tongue), speeding up absorption rate and buying the critically ill very valuable time.

I believe there is a clear unmet need in the marketplace for a novel intravenous aspirin that has a favorable safety profile and will improve the delivery of aspirin especially in patients suffering from acute coronary syndrome, strokes, and pain.  In my opinion, Theaprin’s proprietary improvements (cocrystal technology, special manufacturing process and 100% water solubility) compared to conventional aspirin, will create a tremendous market opportunity for Theaprin, satisfying the unmet need in the marketplace for a novel intravenous aspirin.  Several major drugs are undergoing patent expirations.   As a result, I feel Theaprin’s technology will be very attractive to Big Pharma. – Philip Felice, MD

Theaprin Pharmaceuticals will capitalize on a tremendous market opportunity with their proprietary improvements on traditional aspirin. The current annual worldwide production of aspirin is 100 Billion 500mg tablets.
 

Current aspirin takes 7.5 minutes for the body to absorb. If clinical trials show the favorable results we anticipate, Theaprin is expected to be absorbed in less than 2 minutes. 5 Minutes can make all the difference for someone having a heart attack or stroke.

Theaprin is 100% water soluble and neutral pH, allowing for rapid  intravenous delivery.

Intravenous and sublingual delivery of Theaprin bypasses the stomach, reducing the risk of gastrointestinal bleeding.

Patents Secured: Theaprin Pharmaceuticals has succeeded in securing the following patents, gaining the important first stamp of approval for their life-saving drug.

United States Patent issued May 8, 2012; Patent No. US 8,173,625

United States Patent issued Nov. 6, 2012; Patent No. US 8,304,404

United States Patent issued July 2, 2013; Patent No. US 8,476,250

United States Patent issued April 1, 2014; Patent No. US 8,685,948

Six US Divisional Patent Applications Pending.

National Phase Filings of the Original Patent in 57 Foreign Countries.

    Foreign Patents issued: Australia, New Zealand, Mexico, China, Japan, Canada, Phillippines, Israel, Hong Kong, Europe, and several others pending.

New Patent Application filed March 2015
 

Clinical Trials in Motion: A reputable contract research organization (CRO) has been secured  to facilitate product development through the clinical trial phase and maintain relationships with regulatory agencies.
 

Stability Testing Completed: Theaprin’s chemist has determined that their novel aspirin still passes the USP specification for free salicylic acid, even after being stored under ambient conditions for 4 years. This finding demonstrates the exceedingly high degree of aspirin stability achieved by the Theaprin proprietary formula.
 

GRAS Status Achieved: Our novel formulation does not contain any harmful substances. The proprietary components contained in our formulation have GRAS status (FDA designation for Generally Recognized as Safe) . There is a strong likelihood of expedited approval with United States Food and Drug Administration (FDA), since aspirin is an established drug that has been around for 111 years.

Incentivizing Price Point Determined: Theaprin’s intravenous formulation is expected to be less expensive than intravenous lysine acetylsalicylate (competitor product manufactured outside US and not approved by the FDA). Theaprin’s sublingual formulation is expected to be comparable to conventional aspirin in price.

Theaprin’s chemist has determined that the the Lysine aspirin product sourced from China which is not approved in the US, is a simple salt and not a cocrystal like Theaprin. It is therefore entirely different in nature from the novel Aspirin-Theanine cocrystal product that is owned by Theaprin Pharmaceuticals, Inc. making their product a true category leader.